A

n influential group of clinicians and scientists has come out against a new use for blood-thinning drugs in draft guidelines that could complicate the commercial launch of a recently approved anticoagulant from Portola Pharmaceuticals (PTLA).

The Portola drug, a pill called Bevyxxa, won FDA approval in June to reduce the risk of dangerous blood clots in patients leaving the hospital after treatment for a medical (as opposed to a surgical) illness. The drug failed a phase 3 clinical trial when it didn’t show statistically significant benefits compared to an old generic. But Portola then re-analyzed the data and was able to convince regulators that Bevyxxa provided a benefit over the generic.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Adam, you are an idiot. As usual your articles are filled with hypothesized theories that are based on no facts. You do this because that’s what sells making you a disgrace to journalism. PTLA is unrelated to anticoagulants.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy